UNSPSC 51142318: Naltrexone methobromide

This classification denotes an opiate antagonist with the molecular formula C21H26NO4.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RFO6IL3D3M, chemically known as morphinanium, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-6-oxo-, bromide, (5.alpha.)-, but more generally known as naltrexone methobromide, which bears US NIH Compound Identifier 5361917. European Medicines Agency schedules naltrexone methobromide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09143MIG.

Most nations, for tariff purposes, schedule naltrexone methobromide under HS 29391900. SMILES: C[N+]1(CC[C@]23C4C5CCC(C4O[C@H]2C(=O)CC[C@]3([C@H]1C5)O)O)CC6CC6.[BR-].

UNSPSC 51142318 Naltrexone methobromide is a Commodity code that encompasses pharmaceutical products — specifically naltrexone and related formulations — procured by state and local health agencies, counties, and cooperative purchasing alliances to support public health initiatives, emergency response, and community health programs. State and local governments acquire these medications through competitive bidding processes and cooperative purchasing frameworks, typically as part of broader pharmaceutical supply agreements that include delivery, storage, and compliance requirements such as cGMP certification, DSCSA compliance, and FDA approval. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. Procurement spans both direct purchases of specific unit quantities and framework agreements that establish pricing and supply terms for multiple product lines across authorized wholesalers.

Recent activity shows three distinct procurement approaches: Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to its Community Health Building in Sanford, with a response deadline of July 26, 2023; the Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs without specifying naltrexone explicitly but signaling broader state pharmacy benefit strategy; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP (S1070000015802) on January 20, 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026 and contract effectiveness July 1, 2026, spanning participating states including Oregon and requiring vendors to work through three authorized wholesalers. The geographic concentration spans Florida, Texas, and Minnesota-based cooperatives, with MMCAP serving a multistate footprint. Recent opportunities emphasize compliance with federal regulations, insurance requirements, and wholesaler relationships, with pricing evaluation weighted heavily toward competitiveness and administrative fee structures.